NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SNDX

Syndax Pharmaceuticals Inc

Apr 17 • 04:00PM ET

11.54

Dollar change +0.49
Percentage change 4.43	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY MRK PFE JNJ BMY AMGN GILD REGN VRTX BMRN

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.73	Insider Own	2.18%	Shs Outstand	85.69M	Perf Week	9.70%
Market Cap	992.95M	Forward P/E	-	EPS next Y	-2.80	Insider Trans	-1.55%	Shs Float	84.17M	Perf Month	-12.04%
Income	-318.76M	PEG	-	EPS next Q	-1.27	Inst Own	111.89%	Short Float	23.00%	Perf Quarter	-11.23%
Sales	23.68M	P/S	41.93	EPS this Y	-3.79%	Inst Trans	12.66%	Short Ratio	8.91	Perf Half Y	-41.57%
Book/sh	3.36	P/B	3.43	EPS next Y	27.60%	ROA	-47.66%	Short Interest	19.36M	Perf Year	-45.77%
Cash/sh	6.66	P/C	1.73	EPS next 5Y	26.50%	ROE	-75.69%	52W Range	9.66 - 25.07	Perf YTD	-12.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.16%	ROI	-51.31%	52W High	-53.97%	Beta	0.87
Dividend TTM	-	Quick Ratio	5.82	Sales past 5Y	1801.91%	Gross Margin	-0.68%	52W Low	19.46%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	5.82	EPS Y/Y TTM	-25.83%	Oper. Margin	-1434.43%	RSI (14)	44.37	Volatility	7.10% 8.27%
Employees	270	Debt/Eq	1.20	Sales Y/Y TTM	-	Profit Margin	-1346.11%	Recom	1.23	Target Price	35.25
Option/Short	Yes / Yes	LT Debt/Eq	1.16	EPS Q/Q	-9.84%	Payout	-	Rel Volume	0.90	Prev Close	11.05
Sales Surprise	-78.12%	EPS Surprise	-31.17%	Sales Q/Q	-	Earnings	Mar 03 BMO	Avg Volume	2.17M	Price	11.54
SMA20	-4.49%	SMA50	-14.74%	SMA200	-31.94%	Trades		Volume	1,947,221	Change	4.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Buy	$37
Jun-28-24	Initiated	Jefferies	Buy	$37
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$36 → $23
Dec-22-23	Initiated	Mizuho	Buy	$45
Oct-25-23	Initiated	BofA Securities	Buy	$29
Oct-11-23	Initiated	Goldman	Buy	$30
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy	$40
Apr-17-23	Resumed	BTIG Research	Buy	$34
Jan-31-23	Initiated	Stifel	Buy	$37
Jan-03-23	Initiated	JP Morgan	Overweight	$41
Jul-28-22	Resumed	B. Riley Securities	Buy	$31
Apr-11-22	Initiated	H.C. Wainwright	Buy	$31
Feb-15-22	Initiated	Goldman	Buy	$37
Jun-04-21	Resumed	Robert W. Baird	Outperform	$30 → $31
May-25-21	Initiated	Citigroup	Buy	$24
Feb-18-21	Initiated	B. Riley Securities	Buy	$30
Dec-03-20	Initiated	Stifel	Buy	$32
May-22-20	Upgrade	Citigroup	Neutral → Buy	$26 → $23
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25 → $15

Show Previous Ratings

Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -9.71%
Apr-02-25 07:00AM	Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) +7.99%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha) +7.47%
04:05PM	Loading…
Mar-05-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... (GuruFocus.com)
Mar-03-25 08:15AM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:13AM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-25 07:07AM	Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 07:00AM	Syndax Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-24-25 07:00AM	Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 (GlobeNewswire)
Feb-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-25 07:00AM	Syndax Announces Participation in February Investor Conferences (PR Newswire)
05:34PM	Loading…
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
Jan-13-25 07:00AM	Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-07-25 07:00AM	Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-09-24 07:30AM	Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial (PR Newswire) -8.52%
Dec-07-24 06:15PM	Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting (PR Newswire)
Dec-04-24 01:32PM	Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-27-24 07:00AM	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference (PR Newswire)
Nov-18-24 07:12AM	Syndax secures FDA OK for new kind of leukemia drug (BioPharma Dive)
06:39AM	FDA approves Syndaxs Revuforj to treat leukaemia (Pharmaceutical Technology)
Nov-15-24 05:29PM	Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation (PR Newswire) -5.72%
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-13-24 01:06PM	Syndaxs stock sinks by 25% despite AML trial meeting primary endpoint (Pharmaceutical Technology)
07:21AM	Syndaxs revumenib meets primary results in AML trial (TipRanks)
01:07PM	Loading…
Nov-12-24 01:07PM	Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer (Benzinga) -25.57%
07:00AM	Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib (PR Newswire)
Nov-07-24 12:32AM	Q3 2024 Royalty Pharma PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 12:16PM	Q3 2024 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +8.43%
05:00AM	Moderna said to shuffle sales leadership; Vertex records first Casgevy sale (BioPharma Dive)
02:23AM	Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-05-24 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
09:01AM	Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 (PR Newswire)
09:00AM	Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting (PR Newswire)
09:00AM	Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting (PR Newswire)
04:32AM	Syndax agrees funding with Royalty Pharma for Niktimvo US sales (Pharmaceutical Technology)
Nov-04-24 04:15PM	Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo (GlobeNewswire)
04:01PM	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo (PR Newswire)
Nov-01-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Syndax Announces Participation in November Investor Conferences (PR Newswire)
Oct-29-24 07:00AM	Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 (PR Newswire)
Oct-18-24 03:03PM	State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals (GuruFocus.com)
Oct-09-24 03:54PM	Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-04-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-18-24 05:15PM	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease (PR Newswire)
Sep-06-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 12:01AM	Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-15-24 12:32PM	FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo (Pharmaceutical Technology)
10:11AM	FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication (Benzinga)
Aug-14-24 05:34PM	Incyte and Syndax Announce U.S. FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) (Business Wire)
Aug-12-24 07:00AM	Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia (PR Newswire)
Aug-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -6.56%
Aug-01-24 04:46PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update (PR Newswire)
08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jul-30-24 03:07PM	3 Biotech Stocks That Could Make Your Summer Unforgettable (InvestorPlace)
Jul-29-24 02:42PM	FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks (Investopedia) -10.21%
07:01AM	Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia (PR Newswire)
Jul-25-24 09:55AM	Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet (Zacks)
07:00AM	Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 (PR Newswire)
Jul-09-24 09:55AM	Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade (Zacks) +6.81%
Jul-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-17-24 09:00AM	Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies (GlobeNewswire)
Jun-14-24 07:00AM	Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress (PR Newswire)
Jun-10-24 07:30AM	Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger (GlobeNewswire)
Jun-06-24 07:00AM	Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC (PR Newswire)
Jun-05-24 07:00AM	Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
Jun-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-15-24 04:05PM	Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors (PR Newswire)
May-12-24 08:26AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:00AM	Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference (PR Newswire)
03:03AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:22AM	Syndax Pharmaceuticals Q1 Net Loss Widens (MT Newswires)
07:27AM	Syndax: Q1 Earnings Snapshot (Associated Press Finance)
07:06AM	Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update (PR Newswire)
May-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-01-24 07:00AM	Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Apr-10-24 04:05PM	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum (PR Newswire)
Apr-08-24 07:00AM	Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session (PR Newswire)
Apr-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Mar-28-24 09:54AM	Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA (Zacks)
07:00AM	Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia (PR Newswire)
06:00AM	Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors (GlobeNewswire)
Mar-26-24 04:05PM	Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia (PR Newswire) +7.60%
Mar-18-24 07:00AM	Syndax Announces Appointment of Steven Closter as Chief Commercial Officer (PR Newswire) -6.80%
Mar-03-24 08:29AM	Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Feb-28-24 01:10PM	Q4 2023 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 04:47PM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
Feb-26-24 08:50AM	Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +5.38%
07:00AM	Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Metzger Michael A	Chief Executive Officer	Mar 14 '25	Option Exercise	7.20	6,074	43,733	306,195	Mar 17 06:01 AM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Option Exercise	7.20	7,814	56,261	307,935	Mar 06 04:10 PM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Sale	15.05	7,814	117,564	300,121	Mar 06 04:10 PM
MICHAEL METZGER	Officer	Mar 04 '25	Proposed Sale	15.48	13,888	214,986		Mar 04 05:10 PM
Goldan Keith A.	Chief Financial Officer	Feb 10 '25	Sale	15.50	3,777	58,559	90,746	Feb 12 05:16 PM
Metzger Michael A	Chief Executive Officer	Feb 10 '25	Sale	15.50	13,288	206,017	300,121	Feb 12 05:15 PM
Gallagher Neil	President, Head of R&D	Feb 10 '25	Sale	15.50	4,618	71,597	85,095	Feb 12 05:13 PM
Goldan Keith A.	Officer	Feb 10 '25	Proposed Sale	15.50	3,777	58,559		Feb 10 03:29 PM
Metzger Michael A	Officer	Feb 10 '25	Proposed Sale	15.50	13,288	206,017		Feb 10 03:20 PM
Gallagher Neil	Officer	Feb 10 '25	Proposed Sale	15.50	4,618	71,597		Feb 10 03:17 PM
Goldan Keith A.	Chief Financial Officer	Jun 14 '24	Buy	20.03	1,250	25,037	52,623	Jun 17 09:26 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNDX

Syndax Pharmaceuticals Inc

Upgrade your FINVIZ experience